What is the recommended treatment regimen for an adult male with hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) secondary to systemic lupus erythematosus and Kikuchi‑Fujimoto disease after lymph node biopsy showed necrotizing histiocytic lymphadenitis and was negative for cancer?

Treatment for HLH/MAS Secondary to Lupus and Kikuchi-Fujimoto Disease

The rheumatologist should initiate high-dose pulse methylprednisolone (1 g/day for 3-5 consecutive days) as first-line treatment, with cyclosporine (2-7 mg/kg/day) added immediately if there is insufficient response, and anakinra (2-10 mg/kg/day subcutaneously in divided doses) as a third agent for refractory cases. 1

Treatment Algorithm for MAS-HLH in This Context

First-Line Therapy

The 2019 Blood guidelines explicitly state that corticosteroids are the conventional first-line treatment for MAS-HLH (which is what this patient has, given the underlying lupus and Kikuchi-Fujimoto disease). 1 The standard approach is:

• High-dose pulse methylprednisolone: 1 gram daily for 3-5 consecutive days 1
• This differs from the HLH-94/2004 protocols used for primary HLH, which include etoposide and are designed to bridge to stem cell transplant—not appropriate here 2

Second-Line: Escalation for Insufficient Response

If the patient shows inadequate immediate response to pulse steroids, the guidelines recommend adding:

• Cyclosporine (CSA): 2-7 mg/kg per day 1
• Anakinra (IL-1 blockade): 2-6 mg/kg up to 10 mg/kg per day subcutaneously in divided doses 1

Third-Line: Alternative Biologics

For persistent disease activity:

• Tocilizumab (anti-IL-6): Experience is increasing in MAS-HLH 1
• Emapalumab (anti-IFN-γ): Recent case reports show dramatic efficacy in refractory SLE-associated HLH, including one patient who achieved sustained remission over 17 months 3

Underlying Disease Management

Simultaneously treat the underlying lupus with:

• Hydroxychloroquine: Mandatory for all SLE patients at ≤5 mg/kg real body weight 4
• Immunomodulatory agents (mycophenolate, azathioprine, or cyclophosphamide): These help taper glucocorticoids and control the underlying autoimmune trigger 4, 5, 6

Key Clinical Reasoning

Why This Differs from Primary HLH

The guidelines explicitly state that "treatment of MAS-HLH is different from that recommended for HLH as a result of partial pathogenetic diversity" 1. The initiating factors in MAS-HLH (autoimmune-driven cytokine storm) differ from primary HLH (genetic cytotoxic dysfunction), so the etoposide-based HLH-94/2004 protocols are not the standard approach here 1, 2.

Evidence from Similar Cases

Multiple recent case reports support this graded approach:

• A 15-year-old with the exact same triad (KFD + SLE + MAS) achieved remission with high-dose corticosteroids, IVIG, cyclophosphamide, cyclosporine, and hydroxychloroquine 5
• A 19-year-old with KFD-associated HLH responded to dexamethasone alone (10 mg/m²/day) without etoposide 7
• A 33-year-old with SLE-MAS showed better response to dexamethasone than methylprednisolone 8

Regarding the Lymph Node Excision

The plan for complete lymph node excision by a general oncologist is reasonable for definitive pathologic diagnosis to exclude occult malignancy (which would change the treatment paradigm entirely, as malignancy-associated HLH has the worst prognosis) 1. However, treatment should not be delayed waiting for this procedure if the patient is actively symptomatic with HLH/MAS.

Critical Pitfalls to Avoid

1. Don't wait for complete diagnostic workup to start treatment: MAS-HLH has high mortality if untreated; start pulse steroids immediately if clinical suspicion is high 1

2. Reassess frequently: The guidelines recommend reevaluation at least every 12 hours to determine if escalation is needed 1

3. Monitor for infection triggers: MAS-HLH is commonly triggered by infections, even in autoimmune patients 1. Rule out active infections before intensifying immunosuppression.

4. Taper steroids appropriately: Once remission is achieved, taper glucocorticoids to <7.5 mg/day prednisone equivalent and ideally discontinue, using steroid-sparing agents 4

5. Consider dexamethasone over methylprednisolone: Some evidence suggests dexamethasone may be more effective in MAS-HLH 7, 8, though this is not yet guideline-level evidence

Prognosis Considerations

Adult HLH-associated mortality remains high 1, but MAS-HLH secondary to rheumatic disease generally has better outcomes than malignancy-associated HLH 2. The key to reducing mortality is early recognition and aggressive treatment of both the hyperinflammatory state and the underlying autoimmune condition.